The prognosis of patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) relapse has historically been very poor. Although chemoradiotherapy has improved outcomes, some patients still have a poor prognosis after CNS relapse. Therefore, allogeneic hematopoietic stem cell transplantation (allo-SCT) has recently become an option for treatment of CNS leukemia; however, information, particularly on the long-term outcome of transplant recipients, is limited. We performed allo-SCT in eight pediatric patients with ALL (n ¼ 7) or T-cell type non-Hodgkin's lymphoma (n ¼ 1), who had isolated CNS relapse. All patients survived for a median of 70.5 (range, 13-153) months after SCT. Sequelae developed late in some patients: mental retardation (IQ ¼ 47) in one patient, severe alopecia in two patients, limited chronic graft-versus-host-disease in three patients, and amenorrhea and/or hypothyroidism in three patients. Except for a pre-school child with post transplant CNS relapse, six out of seven patients show normal school/social performance. Our results clearly indicate a high cure rate of isolated CNS relapse by allo-SCT in pediatric lymphoid malignancies; however, there needs to be further studies to determine which are the appropriate candidates for transplantation and what is the best transplant regimen to achieve high cure rate and maintain good quality of life.
Introduction
The cure rate of childhood acute lymphoblastic leukemia (ALL) has improved considerably and approaches 80% today. [1] [2] [3] [4] However, the outcomes of patients who suffer from leukemic relapse remain unsatisfactory. 5 In particular, management of leukemic relapse in the central nervous system (CNS) is problematic for pediatric hemato-oncologists. 5, 6 Although the incidence of CNS relapse as a first event has recently become markedly reduced, 3, [7] [8] [9] optimal therapeutic measures are still needed. 5 Since the late 1950s, standard ALL therapy has consisted of systemic chemotherapy, intrathecal methotrexate (MTX)/hydrocortisone (IT therapy) and CNS irradiation (18) (19) (20) (21) (22) (23) (24) Gy) for prophylaxis of CNS leukemia. 6 More recently, CNS irradiation has been replaced with systemic high-dose MTX, extended IT or additional doses of IT for prophylaxis for most low-risk ALL patients and even some high-risk patients in some protocols. [10] [11] [12] [13] [14] Regardless of these measures, approximately 1-7% of ALL patients still develop CNS relapse. 3, [7] [8] [9] ALL patients with CNS relapse have typically been treated with systemic re-induction chemotherapy and triple intrathecal therapy (MTX/cytosine arabinoside (Ara-C)/hydrocortisone, TIT) followed by cranial or cranio-spinal irradiation and systemic maintenance therapy; 6 however, hematopoietic stem cell transplantations (SCT) have recently been performed in a limited number of patients. [15] [16] [17] [18] [19] [20] [21] [22] Intensive treatment with chemo-radiotherapy in high-risk CNS-relapse patients (i.e. T-cell immunophenotype, first complete remission (CR1) less than 18-24 months, or more than two relapses) 15, 16, 21, 23, 24 has improved outcomes but the majority of these patients have further relapses in the bone marrow, CNS, testis and other sites after attaining CR. Survival has been low in a substantial number of these patients, thus, the outcome is far from desirable. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In addition, poor quality of life (QOL) due to considerable neuropsychological sequelae or mental retardation caused by the additional CNS irradiation and long-term TIT and systemic chemotherapy is problematic in these long-term survivors of CNS relapses. Thus, application of autologous-or allogeneic-SCT (auto-, allo-SCT) in these high-risk patients is expected to result in prompt cure and a shortened postrelapse treatment period with much lower cumulative doses of chemotherapeutic agents. Unfortunately, reports of therapeutic results following SCT in ALL patients with isolated CNS relapse are limited and contradictory, so the exact benefits of transplantation have not yet been clarified. [15] [16] [17] [18] [19] [20] 22 At least two studies have shown a significantly improved outcome in transplant recipients compared to patients treated with chemo-radiotherapy alone. 17, 19 Development of debilitating late sequelae after transplantation procedures is of concern. Since 1992 we have performed allo-SCT in eight patients with lymphoid malignancies for treatment of isolated CNS relapse. Here, we report our SCT results and discuss various problems in the management of isolated CNS relapse in pediatric lymphoid malignancies by reviewing the literature.
Materials and methods
Between 1992 and 2004, 152 cases of ALL (B precursor n ¼ 129, T-cell type n ¼ 14, mature B-cell type n ¼ 6 and mixed lineage type n ¼ 3) and 24 cases of non-Hodgkin's lymphoma (NHL, B precursor n ¼ 5, T-cell type n ¼ 8, mature B-cell type n ¼ 11) were treated in our hospitals. Treatment protocols consisted of systemic induction chemotherapy, CNS prophylaxis (IT therapy with or without cranial irradiation of 18 Gy) and maintenance chemotherapy for a total treatment period of 36-42 months. 34 Of the 176 cases, eight patients (seven ALL and one T-cell type NHL) developed isolated CNS relapse. Thus, the incidence of isolated CNS relapse in our patients was 4.6% for ALL and 4.2% for NHL, respectively. The diagnosis of CNS relapse was made by the presence of X5 leukocytes/ml with identifiable blast cells in the cerebrospinal fluid or the presence of isolated cranial nerve palsy. Table 1 summarizes the disease characteristics of the eight patients (four B precursors and four T-cell types), including CNS prophylactic treatment at the initial therapy. The median onset age of ALL/NHL was 6.5 (range, 2-18) years. At the disease onsets, the white blood cell count in the peripheral blood was a median of 55 470 (range, 3900-419 200)/ml and leukemic involvement in the CNS was detected in three cases (Pts 1, 4 and 8). As CNS prophylaxis/treatment, these eight patients received a median of 9.5 (range, 4-15) doses of intrathecal therapy (IT), two with 18 Gy cranial irradiation, and another two with systemic high dose MTX (1-4 g/m 2 , two to three courses). The duration from the onset to isolated CNS relapse was a median of 17 (range, 3-59) months. Thus, four patients had very early relapse (Pts 1, 4, 5 and 8). 16 Following the diagnosis of CNS relapse, all of the cases received re-induction chemotherapy 34 The post transplant follow-up of patients was a median of 70.5 (range, 13-153) months. Follow-up evaluations include Karnofsky scores, degree of chronic graft-versushost disease (GVHD), physical characteristics (stature, obesity, alopecia), hormonal functions (serum fT4, fT3, TSH, FSH and LH levels), X-rays of the osteoskeletal system, cardio-pulmonary function, brain MRI and school/ social performance. IQ was determined by the TanakaBinet intelligence scale. 
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Results
Allo-SCT characteristics and outcomes are summarized in Table 2 . All patients attained second CR (CR2) prior to transplantation by re-induction chemotherapy and TIT. Additional radiotherapy was given to six patients. Patient 2 received cranial (24 Gy) and spinal (14 Gy) irradiation, which was started 1 month after CNS relapse and 6 months before SCT. Patients 3-6 and 8, who did not receive prophylactic CNS irradiation at disease onset, received pre-transplant 6-12 Gy cranial radiotherapy. In these patients, pre-transplant CNS radiotherapy was performed at a median of 2 (range, 1-11) months from the diagnosis of isolated CNS relapse and was started at a median of 20 (range, 8-21) days before SCT. Although patient 7 had not received prophylactic CNS irradiation, he avoided pre-transplant cranial irradiation due to subclinical leukoencephalopathy diagnosed by brain MRI. The age at SCT was a median of 9 (range, 3-21) years, when the disease status was CR2. All transplants were performed with myeloablative conditioning therapy, which includes fractionated 12 Gy total body irradiation (TBI) (1.5 Gy Â 2/day Â 4 days) without CNS shielding, except for patient 2, since this case already had received both cranial (24 Gy) and spinal (12 Gy) irradiation prior to the conditioning regimens. The bone marrow was obtained from HLA-matched family members for five transplants (Pts 1, 2, 4, 5 and 7) and from an HLA-matched unrelated donor for patient 3. The number of nucleated cells infused in these bone marrow transplant (BMT) patients was a median of 3.9 Â /kg) from an HLAmatched mother. The exact allelic HLA-compatibility of four non-genoidentical donors (Pts 3, 4, 6, and 8) was confirmed by high-resolution DNA typing before SCT in necessary cases. Prophylaxis for acute GVHD consisted of cyclosporin A (2.5-3.0 mg/kg/day, day À1B) and shortcourse MTX, except in patients 4 and 5 who received additional methylprednisolone (5 mg/kg/day, day 7B) 36 and in patient 8 who was given tacrolimus instead of cyclosporin A.
All patients obtained engraftment, with a median time to neutrophil recovery of 12.5 days (range, 9-18 days). Acute GVHD developed in six patients but the grade was less than or equal to grade II except for patient 8 (grade III) who received an HLA one-locus mismatched graft. After a median follow-up of 70.5 (range, 13-153) months, all patients are alive and seven remain in CR post transplant. Patient 7 relapsed in the CNS 7 months after transplantation and is currently in CR under continuous systemic chemotherapy with monthly TIT treatment. Table 3 summarizes the present status of the patients. Neuropsychologic function, growth and hormonal function are most commonly adversely affected in patients who receive SCT. [37] [38] [39] [40] All patients received repeated brain MRI examinations at least twice within 1 year post SCT. Patient 1 presents with mental retardation (IQ ¼ 47) derived from clinically manifested leukoencephalopathy. Six patients (Pts 2-6 and 8) have maintained CR for more than 12 months post transplant and show normal school/social performance. Patient 4 presents with amenorrhea, severe alopecia and short stature (o2 s.d.). Among three patients presenting with a short stature, this patient was confirmed to have growth hormone (GH) deficiency and received GH replacement therapy. Patients 2 and 8 have hypothyroidism, which is treated with thyroid hormone. To date, cardiac or pulmonary dysfunction has not been observed in any patients. Limited chronic GVHD was observed in three patients (Pts 5, 6 and 8) and was treated with corticosteroids.
Discussion
Although the survival rate for isolated CNS relapse patients increased following treatment with a combination Allo-SCT for CNS relapse in ALL T Yoshihara et al of intensive systemic chemotherapy and cranial/craniospinal irradiation with TIT, 6 the final outcomes reported were far from desirable. The event free survival (EFS) at 3-5 years was 46-70%, with a high incidence of later relapse in the CNS and other sites and a high incidence of leukoencephalopathy and second malignancy (Table 4) . 27, 30, 31, 33, 41 Among several reports on the clinical outcome of chemo-radiotherapy, Ritchey et al. 23 reported the best survival (4-year EFS of 71.1%) following intensive chemotherapy and delayed radiotherapy in children with isolated CNS relapse of ALL. According to their data, patients with a short first CR interval of less than 18 months had a poorer therapeutic outcome (EFS of 46.2%) than patients with a longer first CR interval. After considering our own previous observations of dismal outcome in CNS leukemia patients treated with chemoradiotherapy, we employed allo-SCT for treatment of all eight of the isolated CNS relapse cases since 1992. We expected that application of SCT would induce prompt cure with much shorter treatment period and lower cumulative doses of chemotherapeutic agents, compared to patients treated with prolonged chemo-radiotherapy. We selected allo-BMT over auto-BMT to gain an expected antileukemic effect of donor cells through the process of GVHD. 42, 43 Among our patients, three very high-risk patients with very early relapse of T-cell disease (Pts 4, 5 and 8) have been doing well long after SCT. Although our results are based on a small number of patients, allo-SCT may offer an approach that is superior to chemo-radiotherapy in such high-risk patients.
To date, both auto-BMT and allo-BMT have been used to treat isolated CNS leukemia relapses (Table 4) . Including our eight allo-BMTs, a total of 47 auto-BMTs and 94 alloBMTs have been reported for the treatment of isolated CNS leukemia relapse, respectively, in the literature. [15] [16] [17] [18] [19] [20] [21] [22] Owing to the limited number of transplants conducted at various institutes, a direct comparison of therapeutic results following auto-and allo-BMT is impossible. The majority of allo-BMT cases were transplanted with myeloablative regimens and from family donors. However, therapeutic results were contradictory. The SCT results reported by Yumura-Yagi et al. 15 were poor, as only four of the 14 transplant recipients remained in CR while the rest died. The authors did not analyze the reasons for differences between auto-and allo-BMT groups. Based on their report, SCT was not beneficial because the 4-year overall survival (OS) was not significantly different between the SCT (26.8714.2%) and the non-SCT (61.9712.3%) groups in an analysis of 30 CNS relapse cases. In contrast, Messina et al. 19 reported that disease-free survival (DFS) following auto-BMT at 5 years was 56.3%, significantly higher than the 12.6% following chemo-radiotherapy alone. In their series, four of the nine allo-BMT recipients were in CR for 4-5 years. In contrast, Bordigoni et al. 17 reported a better DFS (77.4%) after allo-SCT with a conditioning regimen comprising TBI, high-dose Ara-C and melphalan for children with ALL after isolated CNS relapse within 6 months of the completion of therapy. Our results show all eight allo-BMT recipients are alive and seven are in CR, which is in agreement with the results of Nagatoshi et al., 18 who reported that four of five high-risk allo-BMT recipients were in CR (one of whom had leukoencephalopathy), while one developed another CNS relapse. These results support the effectiveness of allo-BMT from family donors in the treatment of isolated CNS relapse.
Although transplants from unrelated donors (URD) have rarely been reported, when no HLA-matched family donors are available, patients must be evaluated for transplantation suitability and for potential benefit over outcome from treatment with non-transplant chemo-radiotherapy. In the report of Borgmann et al., 16 URD-SCT for patients with isolated extramedullary relapse (not specified as isolated CNS) resulted in survival of three out of five for both URD-transplant and chemotherapy alone groups. In our series, seven received transplants from family donors while only one received a transplant from a URD. The usefulness of URD-SCT remains to be determined for isolated CNS relapse in future studies.
In the management of isolated CNS relapse in pediatric lymphoid malignancies, comparison of late adverse effects, that is, late sequelae in long-term survivors, in addition to survival rate is important in the evaluation of the treatment strategies of chemo-radiotherapy alone versus SCT. In our series, seven of eight recipients are alive in CR off therapy, while one patient relapsed in the CNS and is currently under continuous therapy. This exceptional CNS relapse occurred in patient 7, who did not receive either prophylactic cranial radiation or pre-transplant CNS radiotherapy due to the state of subclinical leukoencephalopathy. Regarding school/social performance, at this time of a 
Allo-SCT for CNS relapse in ALL T Yoshihara et al median of 70.5 (range, 13-153) months post transplant follow-up, one patient presented with mental retardation; the patient had ALL at 2 years of age and received SCT at 3 years of age. 44 This case suggests that CNS therapy with cranial irradiation in very young patients must be performed cautiously to prevent brain damage. Fortunately, the other CR patients have no learning problems or leukoencephalopathy.
According to the report of Bordigoni et al., 17 additional CNS irradiation before the conditioning regimen could be omitted because such measures had no influence on either DFS or on probability of a further relapse in their clinical setting. This contrasted with our results that one out of two patients who did not receive pre-transplant cranial irradiation relapsed in CNS after SCT. The high-dose Ara-C in the conditioning regimen 17 might have acted as a CNSboost for preventing CNS relapse after SCT. This must be confirmed in future studies. Thus, the most important issue to be resolved is if high-dose cranial or cranio-spinal radiotherapy with or without SCT can be omitted to control isolated CNS relapse in pediatric lymphoid malignancies and decrease the incidence of development of late CNS sequelae. Success of SCT without radiotherapy (pre-SCT and/or as a conditioning regimen) must wait for convincing evidence of the graft-versus-leukemia effect in the CNS.
As indicated by Borgmann et al., 16 risk factors should be considered when determining which patients should receive transplants for isolated CNS relapse. Based on the recent risk group classification for relapsed ALL patients, phenotype (non-T or T), relapse site and duration of CR are major prognostic factors, while late isolated CNS relapse is assigned to a low-(standard) risk group. 16 In that case, our patient 3 might have successfully avoided SCT. In addition, three of eight patients with B-cell type ALL had a CR1 lasting more than 24 months and might not represent a good indication for allo-SCT. Taken together, currently recommended strategies for CNS relapses in consideration of risk-groups might be: (1) for high-risk patients (CR1o18 months, T-cell phenotype), allo-SCT from whatever types of donors (URD or genoidentical), and (2) for low-risk patients, either allo-SCT from genoidentical donors or auto-SCT or conventional intensive-chemoradiotherapy with CNS directed maintenance therapy. Detection of minimal residual disease in the bone marrow and/or cerebrospinal fluid might become a new risk factor for selecting patients with isolated CNS relapse who need SCT.
In conclusion, we obtained excellent results from allo-SCT in eight patients with isolated CNS relapse; all of our patients are alive with limited late sequalae and only one patient relapsed after transplantation. In the management of CNS leukemia in childhood, there needs to be further study to determine (1) which are the appropriate candidates for transplantation and (2) what is the best transplant regimen to achieve high cure rate and maintain good QOL.
